,,HMS LINCS,Binding assay,KINOMEScan,,,,,"LSM-1061,LSM-1209,LSM-1141,LSM-1159,LSM-6345,LSM-6303,LSM-6340,LSM-1028,LSM-5613,LSM-1055,LSM-1059,LSM-1060,LSM-1101,LSM-1065,LSM-1066,LSM-1067,LSM-1071,LSM-1092,LSM-1096,LSM-36386,LSM-1002,LSM-1018,LSM-1008,LSM-6015,LSM-1029,LSM-1046,LSM-1049,LSM-1050,LSM-1006,LSM-1009,LSM-1010,LSM-1012,LSM-1013,LSM-5394,LSM-1014,LSM-1027,LSM-5803,LSM-1079,LSM-6343,LSM-6344,LSM-1080,LSM-5970,LSM-1086,LSM-6296,LSM-6297,LSM-6298,LSM-6299,LSM-6300,LSM-1064,LSM-1104,LSM-6308,LSM-6306,LSM-6305,LSM-6304,LSM-1073,LSM-1230,LSM-1190,LSM-1106,LSM-1058,LSM-1051,LSM-1068,LSM-1001,LSM-6711,LSM-6712,LSM-1173,LSM-1047,LSM-1093,LSM-4255,LSM-1094,LSM-1224,LSM-1147,LSM-1035,LSM-5577,LSM-1025,LSM-1163,LSM-1210,LSM-1214,LSM-5982,LSM-5431,LSM-5245,LSM-1026,LSM-1085,LSM-5545,LSM-1070,LSM-1045,LSM-1043,LSM-1041,LSM-1003,LSM-1215,LSM-1120,LSM-5674,LSM-1024,LSM-1040,LSM-1129,LSM-1172,LSM-1105,LSM-1213,LSM-6709,LSM-36387,LSM-1184,LSM-1053,LSM-5749",,,
,,HMS LINCS,Binding assay,KiNativ,,,"Cervix,Prostate,Blood,Breast,Blood,Nervous system","HeLa,PC-3,Ramos (RA 1),MDA-MB-468,BCWM.1,NGP","LSM-1080,LSM-1106,LSM-1086,LSM-1008,LSM-1029,LSM-1046,LSM-1049,LSM-1050,LSM-1068,LSM-1079,LSM-1092,LSM-1070,LSM-5577,LSM-1093,LSM-1094,LSM-6299,LSM-1202,LSM-1201,LSM-6015,LSM-6708,LSM-6340,LSM-5803,LSM-1129,LSM-1189","Adenocarcinoma,Prostate adenocarcinoma,Burkitts lymphoma,Breast adenocarcinoma,Lymphoplasmacytic lymphoma,Neuroblastoma",,
LDS-1002,20001,HMS LINCS,Imaging,Fluorescence,9/25/15,11/13/15,"Lung,Skin","PC-9,NCI-H1648,NCI-H1648,IST-MEL1,IA-LM,COLO-800","LSM-1104,LSM-1041,LSM-1105,LSM-1103,LSM-1014,LSM-1021,LSM-1106,LSM-1102","Adenocarcinoma,Lung adenocarcinoma","melanoma,lung large cell carcinoma",Fluorescence imaging apoptosis assay
LDS-1003,20002,HMS LINCS,Imaging,Fluorescence,2/7/14,9/3/15,epitheloid,"SK-LMS-1,NCI-H810,KYSE-180,KYSE-140,HUTU-80,BPH-1,5637 (LCL-1702)","LSM-1104,LSM-1041,LSM-1105,LSM-1103,LSM-1014,LSM-1021,LSM-1106,LSM-1102","Non-small cell lung carcinoma, Squamous cell carcinoma, Adenocarcinoma,Male reproductive benign neoplasm,Transitional cell carcinoma","Moerke 3 Color Apoptosis: Dose response of anti-mitotic compounds in human cancer cell lines at 24 and 48 hours to determine their effects on apoptosis and cell death.  In this assay, the cell-permeable DNA dye Hoechst 33342 is used to stain the nuclei of all cells.  The fluorescent caspase 3 reporter NucView488 stains the nuclei of cells undergoing apoptosis (in which caspase 3 is active), and the cell-impermeable DNA dye TO-PRO3 stains only the nuclei of dead or dying cells in which membrane integrity is compromised.",Fluorescence imaging apoptosis assay
LDS-1004,20003,HMS LINCS,Imaging,Fluorescence,2/7/14,9/3/15,"Intestine,Urinary bladder,Breast,Ovary,Pancreas,Lung,Breast,Brain,Esophagus,Kidney,Liver,Uterus, Stomach,Skin,Cervix,Stomach","WiDr,T24,SW620,SW527,SK-OV-3,PL4,PE/CA-PJ15,NCI-H2023,NCI-H1915,NCI-H1651,MT-3,MDA-MB-435S,LNZTA3WT4,KYSE-450,KYSE-150,KYSE-140,KMRC-20,JHH-6,Ishikawa (Heraklio) 02 ER-,Ishikawa,HLF,HEC-1,FU97,COLO-679,Calu-3,Calu-1,CAL-51,Ca9-22,Ca Ski,AGS,A375.S2,647-V,5637(LCL-1702)","LSM-1041,LSM-1066,LSM-1021,LSM-1062,LSM-1067,LSM-1065,LSM-1105,LSM-1102","Adenocarcinoma,Transitional cell carcinoma,Carcinoma,Squamous cell,Carcinoma, Non-small cell lung carcinoma, Melanoma, Glioblastoma, Hepatocellular carcinoma, Endometrial adenocarcinoma, Lung squamous cell carcinoma,Gum cancer,Cervical squamous cell carcinoma, Gastric adenocarcinoma","Tang Mitosis/Apoptosis ver.II: Dose response of anti-mitotic compounds in human cancer cell lines at 24, 48 and 72 hours to determine effect on apoptosis, mitosis and cell death. In screening for small-molecule compounds that are effective at killing cancer cells, one-dimensional readout GI50, which is the EC50 value of growth inhibition, is usually used as the only criterion. A major problem with this one-readout approach is that other useful information is discarded, which could be critical for understanding the action of the compounds. In this screen, we use a single-cell-based imaging assay that can report multi-dimensional physiological responses in cells treated with small molecule kinase inhibitors. The data in this dataset are described in PMID: 23788527: Differential Determinants of Cancer Cell Insensitivity to Antimitotic Drugs Discriminated by a One-Step Cell Imaging Assay (J. Biomolecular Screening, 2013). The image analysis algorithm is available at https://github.com/xietiao/Tang_et_al_LINCS_cell_scoring.",Fluorescence imaging apoptosis assayLDS-1005,20004,HMS LINCS,Imaging,Fluorescence,2/7/14,9/3/15,"Brain,Lung,Muscle,Esophagus,Stomach,Skin,Intestine,Prostate,Urinary bladder","SNB75,SK-MES,SK-LMS-1,SJCRH30,PC-9,NCI-H810,NCI-H1703,NCI-H1648,KYSE-180,KYSE-140,KATO III,IST-MEL1,IA-LM,HUTU-80,COLO-800,BPH-1,5637(LCL-1702)","LSM-1104,LSM-1041,LSM-1105,LSM-1103,LSM-1014,LSM-1021,LSM-1106,LSM-1102","Glioblastoma,Lung squamous cell carcinoma,Rhabdomyosarcoma,Non-small cell lung carcinoma,Adenocarcinoma,Gastric signet ring cell adenocarcinoma,Melanoma,Lung large cell carcinoma,Male reproductive benign neoplasm,Transitional cell carcinoma",,Fluorescence imaging cell cycle state assay
LDS-1106,20120,HMS LINCS,Imaging,Analysis,5/2/14,9/3/15,Breast,"ZR75B,LY2,HCC3153,HCC2185,600MPE,T47DKBLUC,MX-1,MCF12A,184A1,SUM52PE,SUM229PE,SUM225CWN,SUM185PE,SUM159PT,SUM149PT,SUM1315MO2,MCF10F,MCF10A,HCC1187,184B5,ZR-75-1,UACC-893,UACC-812,T47D,MDA-MB-468,MDA-MB-453,MDA-MB-436,MDA-MB-361,MDA-MB-175-VII,MDA-MB-157,MDA-MB-134-VI,MB157,Hs578T,HCC70,HCC38,HCC202,HCC1954,HCC1937,HCC1806,HCC1569,HCC1428,HCC1419,HCC1395,HCC1143,CAMA-1,BT-549,BT-483,BT-474,BT-20,AU565,MDA-MB-231,SK-BR-3,MCF7","LSM-1013,LSM-1021,LSM-1023,LSM-1026,LSM-1035,LSM-1062,LSM-1097,LSM-1098,LSM-1102,LSM-1107,LSM-1108,LSM-5742,LSM-1143,LSM-1147,LSM-1173,LSM-1176,LSM-1190,LSM-1224,LSM-2309,LSM-1231,LSM-4258,LSM-5870,LSM-6359,LSM-4261,LSM-6281,LSM-4265,LSM-4266,LSM-4267,LSM-4268,LSM-2167,LSM-6360,LSM-4062,LSM-2078,LSM-6348,LSM-4272,LSM-5333,LSM-4276,LSM-4278,LSM-4279,LSM-5732,LSM-6350,LSM-4284,LSM-6263,LSM-2042,LSM-4287,LSM-6351,LSM-6352,LSM-4290,LSM-6361,LSM-6362,LSM-4295,LSM-5662,LSM-3524,LSM-3810,LSM-6302,LSM-3828,LSM-4298,LSM-6355,LSM-6356,LSM-6357,LSM-6363,LSM-6358","Acantholytic variant squamous cell breast carcinoma,Adenocarcinoma,Breast adenocarcinoma,Breast carcinoma,Breast medullary carcinoma,Breast metaplastic carcinoma,Fibrocystic disease,Invasive ductal carcinoma",Metrics other than potency reveal systematic variation in responses to cancer drugs,Fluorescence imaging apoptosis assay
LDS-1122,20136,HMS LINCS,Imaging,Fluorescence,2/7/14,9/3/15,Breast,"T47D,MCF10A,HCC1954,AU565","LSM-1098,LSM-6357,LSM-42798,LSM-1057,LSM-4255","Breast carcinoma,Fibrocystic disease,Invasive ductal carcinoma,Breast adenocarcinoma",Breast cell line dose response to target inhibition measured by high throughput microscopy,Fluorescence imaging Protein_Metadata.txt state assay
LDS-1123,20137,HMS LINCS,Binding assay,ELISA,9/23/15,11/13/15,Breast,"184B5,AU565,BT-20,BT-474,BT-483,BT-549,CAMA-1,HCC1187,HCC1395,HCC1419,HCC1428,HCC1500,HCC1569,HCC1806,HCC1937,HCC1954,HCC202,HCC38,HCC70,Hs 578T,MCF 10A,MCF 10F,MCF12A,MCF7,MDA-MB-134-VI,MDA-MB-157,MDA-MB-175-VII,MDA-MB-231,MDA-MB-361,MDA-MB-415,MDA-MB-436,MDA-MB-453,MDA-MB-468,SK-BR-3,T47D,UACC-812,UACC-893,ZR-75-1,ZR-75-30",,,Basal profile of receptor tyrosine kinase signaling network measured by ELISA,ELISA Protein_Metadata.txt state assay
LDS-1124,20138,HMS LINCS,Imaging,Immunofluorescence,5/22/14,9/3/15,Breast,"ZR-75-30,ZR-75-1,UACC-893,UACC-812,T47D,SK-BR-3,MDA-MB-453,MDA-MB-415,MDA-MB-361,MDA-MB-231,MDA-MB-175-VII,MDA-MB-157,MDA-MB-134-VI,MCF7,MCF12A,MCF 10F,MCF 10A,Hs 578T,HCC70,HCC38,HCC202,HCC1954,HCC1937,HCC1806,HCC1569,HCC1500,HCC1428,HCC1419,HCC1395,HCC1187,CAMA-1,BT-549,BT-483,BT-474,BT-20,AU565,184B5",,"Invasive ductal carcinoma,Fibrocystic disease,Breast metaplastic carcinoma,Breast medullary carcinoma,Breast carcinoma,Breast adenocarcinoma,Adenocarcinoma,Acantholytic variant squamous cell breast carcinoma",Cell signaling response to growth factors measured by high throughput microscopy,Fluorescence imaging Protein_Metadata.txt state assay
LDS-1125,20139,HMS LINCS,Imaging,Immunofluorescence,5/22/14,9/3/15,Breast,"ZR-75-30,ZR-75-1,UACC-893,UACC-812,T47D,SK-BR-3,MDA-MB-453,MDA-MB-415,MDA-MB-361,MDA-MB-231,MDA-MB-175-VII,MDA-MB-157,MDA-MB-134-VI,MCF7,MCF12A,MCF 10F,MCF 10A,Hs 578T,HCC70,HCC38,HCC202,HCC1954,HCC1937,HCC1806,HCC1569,HCC1500,HCC1428,HCC1419,HCC1395,HCC1187,CAMA-1,BT-549,BT-483,BT-474,BT-20,AU565,184B5",,"Invasive ductal carcinoma,Fibrocystic disease,Breast metaplastic carcinoma,Breast medullary carcinoma,Breast carcinoma,Breast adenocarcinoma,Adenocarcinoma,Acantholytic variant squamous cell breast carcinoma",Cell signaling response to cytokines measured by high throughput microscopy,Fluorescence imaging Protein_Metadata.txt state assay
LDS-1126,20140,HMS LINCS,Binding assay,ELISA,9/23/15,11/13/15,Breast,"184B5,AU565,AU565,BT-20,BT-474,BT-483,BT-549,CAMA-1,HCC1187,HCC1395,HCC1419,HCC1428,HCC1500,HCC1569,HCC1806,HCC1937,HCC1954,HCC202,HCC38,HCC70,Hs 578T,MCF 10A,MCF 10F,MCF12A,MCF7,MCF7,MDA-MB-134-VI,MDA-MB-231,MDA-MB-231,MDA-MB-361,MDA-MB-415,MDA-MB-436,MDA-MB-453,MDA-MB-468,SK-BR-3,SK-BR-3,T47D,UACC-812,UACC-893,ZR-75-1,ZR-75-30",,Adenocarcinoma,,ELISA Protein_Metadata.txt state assay
LDS-1191,,BroadT LINCS,Transcriptomics,L1000,,,"Blood,Breast,Intestine,Liver,lung,lymphatic system,muscle,nervous system,ovary,prostate,skin,stomach,uterus","WSU-DLCL2, Huh7,SNG-M,DV-90,NCI-H596,HT115,VCaP, A549, A-375,BT-20 ,MDST8,SW-948,SK-MEL-1,NCI-H716,HT-29,U-937,SW620,Hep G2,A673,HCT 116,SK-BR-3,MDA-MB-231,EFO-27,HCC-15,RMG-I,MCF7,THP-1,PC-3,NCI-H2073,TYK-nu,AGS,SH-SY5Y,Hs 578T,NCI-H1694,LoVo,COR-L23,NCI-H1836,NOMO-1,SK-LU-1",txt file,"Acute myeloid leukemia,Adenocarcinoma,Adenosquamous cell lung carcinoma,B-cell lymphocytic neoplasm,Breast carcinoma,Cecum adenocarcinoma,Colon carcinoma,Diffuse large B-cell lymphoma, Endometrial adenocarcinoma,Gastric adenocarcinoma,Hepatocellular carcinoma,Invasive ductal carcinoma,Lung adenocarcinoma,Lung large cell carcinoma,Lung small cell carcinoma melanoma,Neuroblastoma,Non-small cell lung carcinoma,Ovarian carcinoma,Ovarian clear cell adenocarcinoma,Ovary adenocarcinoma,Prostate adenocarcinoma,Prostate carcinoma,Rhabdomyosarcoma",L1000 perturbational profiles,L1000 mRNA profiling assay
LDS-1194,,BroadT LINCS,Transcriptomics,L1000,,,Bone,U-2 OS,txt file,Osteosarcoma,L1000 perturbational profiles,L1000 mRNA profiling assay
LDS-1195,,LINCS PCCSE,Imaging,Immunofluorescence,,,Bone,U-2 OS,txt file,Osteosarcoma,Fluorescence Imaging Multiplex Cytological Profiling Assay,Fluorescence imaging multiplex cytological profiling assay
LDS-1196,,BroadT LINCS,Epigenomics,P100,,,"Breast, Prostate, Blood","MCF7, PC-3, HL-60","LSM-2962,LSM-4062,LSM-2499,LSM-2167,LSM-5496,LSM-6504,LSM-6504,LSM-2405,LSM-2401,LSM-5044,LSM-5427,LSM-5886,LSM-5082,LSM-5427,LSM-2962,LSM-5082,LSM-2511","Adenocarcinoma, Prostate adenocarcinoma, Acute myeloid leukemia",P100 Phosphosite Profiling Assay,P100 phosphoProtein_Metadata.txt quantification assay
LDS-1202,,BroadT LINCS,Transcriptomics,L1000,,,"Breast,Prostate","BT-20, LNCaP, SK-BR-3, MDA-MB-231, MCF7, Hs578T","LSM-1079,LSM-1064,LSM-1047,LSM-5068,LSM-1183,LSM-1057,LSM-1057,LSM-1079,LSM-1047,LSM-1064,LSM-1047,LSM-1183","Breast carcinoma, Prostate carcinoma, Breast adenocarcinoma, Breast invasive ductal carcinoma",,L1000 mRNA profiling assay
LDS-1203,,BroadT LINCS,Transcriptomics,L1000,,,Breast,"BT-20,SK-BR-3,MDA-MB-231,MCF7,Hs578T","LSM-1054,LSM-1066,LSM-1006,LSM-6019,LSM-1032,LSM-1162,LSM-1040,LSM-5749,LSM-1062,LSM-1026,LSM-1096,LSM-1022,LSM-1044,LSM-1049,LSM-5067,LSM-1018,LSM-5245,LSM-1120,LSM-5982,LSM-1051,LSM-5394,LSM-1074,LSM-1093,LSM-1056,LSM-1053,LSM-1011,LSM-5970,LSM-5674,LSM-1177,LSM-1004,LSM-1011,LSM-1070,LSM-1166,LSM-1070,LSM-1003,LSM-1026,LSM-1026,LSM-1041,LSM-1035,LSM-1003,LSM-1035,LSM-1043,LSM-1180,LSM-1042,LSM-1079,LSM-1085,LSM-1043,LSM-1024,LSM-1020,LSM-1013,LSM-1024,LSM-1069,LSM-1064,LSM-1097,LSM-1134,LSM-1180,LSM-1024,LSM-1086,LSM-5613,LSM-1182,LSM-1081,LSM-1048,LSM-1094,LSM-1032,LSM-1026,LSM-1023,LSM-1072,LSM-1023,LSM-1060,LSM-1012,LSM-1118,LSM-1049,LSM-1058,LSM-1023,LSM-1074,LSM-1074,LSM-1139,LSM-1031,LSM-1098,LSM-1094,LSM-1096,LSM-1136,LSM-1047,LSM-1006,LSM-1024,LSM-1133,LSM-1045,LSM-1114,LSM-1097,LSM-1096,LSM-1054,LSM-1056,LSM-1065,LSM-1136,LSM-1169,LSM-1031,LSM-1068,LSM-1020,LSM-1009,LSM-1121,LSM-1183,LSM-1037,LSM-1161,LSM-5610,LSM-1041,LSM-1046,LSM-1013,LSM-1050,LSM-1157,LSM-1080,LSM-1055,LSM-1009,LSM-1101,LSM-1042,LSM-1012,LSM-1026,LSM-5610,LSM-1130,LSM-1152,LSM-1096,LSM-1131,LSM-1153,LSM-1010,LSM-1057,LSM-1130,LSM-1007,LSM-5006,LSM-1059,LSM-1005,LSM-1085,LSM-1057,LSM-1048,LSM-1161,LSM-1079,LSM-1002,LSM-1101,LSM-1081,LSM-1162,LSM-1085,LSM-1086,LSM-1068,LSM-1037,LSM-1127,LSM-1161,LSM-1005,LSM-1011,LSM-1047,LSM-1034,LSM-1061,LSM-1153,LSM-1069,LSM-1142,LSM-1028,LSM-1054,LSM-1182,LSM-1023,LSM-1040,LSM-1027,LSM-1063,LSM-1115,LSM-1061,LSM-1161,LSM-1099,LSM-1007,LSM-1120,LSM-1036,LSM-1073,LSM-1027,LSM-1098,LSM-1026,LSM-1051,LSM-1097,LSM-1028,LSM-1044,LSM-1023,LSM-1062,LSM-1053,LSM-1010,LSM-1033,LSM-1036,LSM-1166,LSM-1134,LSM-1064,LSM-1101,LSM-1033,LSM-1034,LSM-1177,LSM-1160,LSM-1178,LSM-1053,LSM-1067,LSM-1073,LSM-1049,LSM-1169,LSM-1080,LSM-1018,LSM-1048,LSM-5803,LSM-1067,LSM-1115,LSM-1045,LSM-1051,LSM-1056,LSM-1093,LSM-1065,LSM-1012,LSM-1022,LSM-1142,LSM-1114,LSM-1025,LSM-1069,LSM-1058,LSM-1046,LSM-1047,LSM-1098,LSM-1172,LSM-1031,LSM-1192,LSM-1067,LSM-1157,LSM-1060,LSM-1139,LSM-1010,LSM-1183,LSM-1055,LSM-1036,LSM-1172,LSM-1023,LSM-1059,LSM-1068,LSM-1059,LSM-1139,LSM-1098,LSM-1050,LSM-1170,LSM-1158,LSM-1127,LSM-1072,LSM-1032,LSM-1071,LSM-1121,LSM-1071,LSM-1192,LSM-1004,LSM-1063,LSM-1002,LSM-1151,LSM-1042,LSM-1099,LSM-1066,LSM-1011,LSM-1025","Breast carcinoma,Adenocarcinoma,Invasive ductal carcinoma",L1000 gene expression profiling assay - LJP,L1000 mRNA profiling assay
LDS-1206,20215,HMS LINCS,Imaging,Immunofluorescence,7/1/15,9/3/15,Breast,"MDA-MB-231, HME1","LSM-1047,LSM-1057,LSM-1064,LSM-1079,LSM-1101",Adenocarcinoma,Sensitivity measures of MDA-MB-231 and HME-1 cell lines to LINCS Pilot Phase TransCenter Project kinase inhibitors,Fluorescence imaging apoptosis assay
LDS-1207,20216,HMS LINCS,Imaging,Analysis,7/1/15,9/3/15,Breast,"MDA-MB-231, HME1","LSM-1047,LSM-1057,LSM-1101,LSM-1079,LSM-1064",Adenocarcinoma,Metrics for growth responses of MDA-MB-231 and HME-1 cell lines to LINCS Pilot Phase TransCenter Project kinase inhibitors,Fluorescence imaging apoptosis assay
LDS-1208,20217,HMS LINCS,Imaging,Fluorescence,4/10/15,9/3/15,Skin,"SKMEL28,K2,MZ7-mel,MMAC-SF,LOXIMVI,WM1552C,WM-115,RVH-421,COLO858,C32","LSM-1046,LSM-1049,LSM-1050,LSM-1056,LSM-1068",Melanoma,Viability and apoptosis in BRAF(V600E/D) melanoma cell lines monitored by imaging,Fluorescence imaging apoptosis assay
LDS-1209,20218,HMS LINCS,Proteomics,Reverse Phase Protein Array,8/25/15,9/3/15,Skin,"SKMEL28,K2,MZ7-mel,MMAC-SF,LOXIMVI,WM1552C,WM-115,RVH-421,COLO858,C32","LSM-1046,LSM-1049,LSM-1050,LSM-1056,LSM-1068",Melanoma,Phosphorylation state and protein levels measured in BRAF(V600E/D) melanoma cell lines monitored by Reverse Phase Protein Arrays (RPPA),RPPA Protein_Metadata.txt state assay
LDS-1210,20219,HMS LINCS,Imaging,Immunofluorescence,4/10/15,9/3/15,Skin,"WM1552C,WM-115,LOXIMVI,COLO858","LSM-1068,LSM-36360",Melanoma,Phosphorylation state and protein levels measured in BRAF(V600E/D) melanoma cell lines monitored by imaging,Fluorescence imaging Protein_Metadata.txt state assay
LDS-1219,20229,HMS LINCS,Imaging,Analysis,4/17/15,9/3/15,Skin,"WM1552C,WM-115,SKMEL28,RVH-421,MZ7-mel,MMAC-SF,LOXIMVI,K2,COLO858,C32",,Melanoma,PLSR model loadings (pMEK and pERK included) from analysis of the covariation of molecular signals with cell viability and apoptosis fraction in BRAF(V600E/D) melanoma cell lines,Fluorescence imaging apoptosis assay
LDS-1220,20230,HMS LINCS,Imaging,Analysis,4/17/15,9/3/15,Skin,"WM1552C,WM-115,SKMEL28,RVH-421,MZ7-mel,MMAC-SF,LOXIMVI,K2,COLO858,C32",,Melanoma,PLSR model loadings (pMEK and pERK excluded) from analysis of the covariation of molecular signals with cell viability and apoptosis fraction in BRAF(V600E/D) melanoma cell lines,Fluorescence imaging apoptosis assay
LDS-1221,20231,HMS LINCS,Imaging,Analysis,4/17/15,9/3/15,Skin,"WM1552C,WM-115,SKMEL28,RVH-421,MZ7-mel,MMAC-SF,LOXIMVI,K2,COLO858,C32",,Melanoma,Average variable importance in the projection (VIP) scores from the PLSR models analyzing the covariation of molecular signals with cell viability and apoptosis fraction in BRAF(V600E/D) melanoma cell lines,Fluorescence imaging apoptosis assay
LDS-1222,20232,HMS LINCS,Imaging,Analysis,7/2/15,9/3/15,Cervix,HeLa,LSM-6281,Cervical adenocarcinoma,Live-cell imaging of cell-to-cell variability in caspase-8 FRET reporter activity and cell fate trajectory modeling,Fluorescence imaging apoptosis assay
LDS-1223,20233,HMS LINCS,Proteomics,Immunoassay,8/27/15,9/3/15,Synovium,"N2586,RA2159","LSM-1048,LSM-1231,LSM-1139,LSM-1227,LSM-2309,LSM-1228,LSM-1126,LSM-1035,LSM-36360",Rheumatoid arthritis,Synovial Fibroblast 1: Secretion response of primary human synovial fibroblast samples from one healthy and one rheumatoid arthritis donor to a panel of 10 stimuli and 10 small molecule inhibitors,Bead-based immunoassay for Protein_Metadata.txt state
LDS-1224,20234,HMS LINCS,Proteomics,Immunoassay,7/15/15,9/3/15,Synovium,"N2586,RA2159","LSM-36360,LSM-6712,LSM-2309,LSM-1227",Rheumatoid arthritis,Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2),Bead-based immunoassay for Protein_Metadata.txt state
LDS-1225,20235,HMS LINCS,Proteomics,Immunoassay,7/16/15,9/3/15,Synovium,"N2586,RA2159","LSM-36360,LSM-6712,LSM-2309,LSM-1227",Rheumatoid arthritis,Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2),Bead-based immunoassay for Protein_Metadata.txt state
LDS-1226,20237,HMS LINCS,Imaging,Immunofluorescence,8/25/15,9/3/15,Breast,"MCF7,SK-BR-3,MDA-MB-231,BT-20,Hs578T,MCF10A","LSM-5742,LSM-1035,LSM-1011,LSM-1004,LSM-1159,LSM-1059,LSM-1006,LSM-1007,LSM-1165,LSM-1067,LSM-1041,LSM-1028,LSM-1132,LSM-4257,LSM-1122,LSM-1046,LSM-1191,LSM-1031,LSM-4256,LSM-1162,LSM-1045,LSM-1063,LSM-5577,LSM-6015,LSM-5431,LSM-5545,LSM-6299,LSM-1178,LSM-1148,LSM-1055,LSM-1120,LSM-1117,LSM-1025,LSM-1181,LSM-1010,LSM-1009,LSM-1027,LSM-1141,LSM-1020,LSM-1127,LSM-1069,LSM-1097,LSM-1158,LSM-1040,LSM-1047,LSM-1098,LSM-1108,LSM-1173,LSM-1134,LSM-1147,LSM-1128,LSM-1014,LSM-5982,LSM-5245,LSM-1023,LSM-36386,LSM-5674,LSM-1051,LSM-1115,LSM-1183,LSM-1135,LSM-1057,LSM-1018,LSM-1099,LSM-1152,LSM-1061,LSM-4255,LSM-1024,LSM-1071,LSM-1101,LSM-1026,LSM-1048,LSM-1160,LSM-1116,LSM-1112,LSM-1072,LSM-1125,LSM-1073,LSM-1126,LSM-1049,LSM-5803,LSM-6019,LSM-1001,LSM-1139,LSM-1149,LSM-1032,LSM-1056,LSM-1052,LSM-1008,LSM-1119,LSM-1142,LSM-1172,LSM-1079,LSM-1080,LSM-1021,LSM-1143,LSM-1111,LSM-1068,LSM-1064,LSM-5970,LSM-1086,LSM-1150,LSM-1109,LSM-1053",Breast cancer,LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1.,Fluorescence imaging apoptosis assay
LDS-1227,20238,HMS LINCS,Imaging,Immunofluorescence,8/25/15,9/3/15,Breast,"MCF7,SK-BR-3,MDA-MB-231,BT-20,Hs578T,MCF10A","LSM-5742,LSM-1035,LSM-1011,LSM-1004,LSM-1159,LSM-1059,LSM-1006,LSM-1007,LSM-1165,LSM-1067,LSM-1041,LSM-1028,LSM-1132,LSM-4257,LSM-1122,LSM-1046,LSM-1191,LSM-1031,LSM-4256,LSM-1162,LSM-1045,LSM-1063,LSM-5577,LSM-6015,LSM-5431,LSM-5545,LSM-6299,LSM-1178,LSM-1148,LSM-1055,LSM-1120,LSM-1117,LSM-1025,LSM-1181,LSM-1010,LSM-1009,LSM-1027,LSM-1141,LSM-1020,LSM-1127,LSM-1069,LSM-1097,LSM-1158,LSM-1040,LSM-1047,LSM-1098,LSM-1108,LSM-1173,LSM-1134,LSM-1147,LSM-1128,LSM-1014,LSM-5982,LSM-5245,LSM-1023,LSM-36386,LSM-5674,LSM-1051,LSM-1115,LSM-1183,LSM-1135,LSM-1057,LSM-1018,LSM-1099,LSM-1152,LSM-1061,LSM-4255,LSM-1024,LSM-1071,LSM-1101,LSM-1026,LSM-1048,LSM-1160,LSM-1116,LSM-1112,LSM-1072,LSM-1125,LSM-1073,LSM-1126,LSM-1049,LSM-5803,LSM-6019,LSM-1001,LSM-1139,LSM-1149,LSM-1032,LSM-1056,LSM-1052,LSM-1008,LSM-1119,LSM-1142,LSM-1172,LSM-1079,LSM-1080,LSM-1021,LSM-1143,LSM-1111,LSM-1068,LSM-1064,LSM-5970,LSM-1086,LSM-1150,LSM-1109,LSM-1053",Breast cancer,LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2.,Fluorescence imaging apoptosis assay
LDS-1228,20239,HMS LINCS,Imaging,Immunofluorescence,8/25/15,9/3/15,Breast,"MCF7,SK-BR-3,MDA-MB-231,BT-20,Hs578T,MCF10A","LSM-5742,LSM-1035,LSM-1011,LSM-1004,LSM-1159,LSM-1059,LSM-1006,LSM-1007,LSM-1165,LSM-1067,LSM-1041,LSM-1028,LSM-1132,LSM-4257,LSM-1122,LSM-1046,LSM-1191,LSM-1031,LSM-4256,LSM-1162,LSM-1045,LSM-1063,LSM-5577,LSM-6015,LSM-5431,LSM-5545,LSM-6299,LSM-1178,LSM-1148,LSM-1055,LSM-1120,LSM-1117,LSM-1025,LSM-1181,LSM-1010,LSM-1009,LSM-1027,LSM-1141,LSM-1020,LSM-1127,LSM-1069,LSM-1097,LSM-1158,LSM-1040,LSM-1047,LSM-1098,LSM-1108,LSM-1173,LSM-1134,LSM-1147,LSM-1128,LSM-1014,LSM-5982,LSM-5245,LSM-1023,LSM-36386,LSM-5674,LSM-1051,LSM-1115,LSM-1183,LSM-1135,LSM-1057,LSM-1018,LSM-1099,LSM-1152,LSM-1061,LSM-4255,LSM-1024,LSM-1071,LSM-1101,LSM-1026,LSM-1048,LSM-1160,LSM-1116,LSM-1112,LSM-1072,LSM-1125,LSM-1073,LSM-1126,LSM-1049,LSM-5803,LSM-6019,LSM-1001,LSM-1139,LSM-1149,LSM-1032,LSM-1056,LSM-1052,LSM-1008,LSM-1119,LSM-1142,LSM-1172,LSM-1079,LSM-1080,LSM-1021,LSM-1143,LSM-1111,LSM-1068,LSM-1064,LSM-5970,LSM-1086,LSM-1150,LSM-1109,LSM-1053",Breast cancer,LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3.,Fluorescence imaging apoptosis assay
LDS-1229,20240,HMS LINCS,Imaging,Immunofluorescence,8/25/15,9/3/15,Breast,"MCF7,SK-BR-3,MDA-MB-231,BT-20,Hs578T,MCF10A","LSM-5742,LSM-1035,LSM-1011,LSM-1004,LSM-1159,LSM-1059,LSM-1006,LSM-1007,LSM-1165,LSM-1067,LSM-1041,LSM-1028,LSM-1132,LSM-4257,LSM-1122,LSM-1046,LSM-1191,LSM-1031,LSM-4256,LSM-1162,LSM-1045,LSM-1063,LSM-5577,LSM-6015,LSM-5431,LSM-5545,LSM-6299,LSM-1178,LSM-1148,LSM-1055,LSM-1120,LSM-1117,LSM-1025,LSM-1181,LSM-1010,LSM-1009,LSM-1027,LSM-1141,LSM-1020,LSM-1127,LSM-1069,LSM-1097,LSM-1158,LSM-1040,LSM-1047,LSM-1098,LSM-1108,LSM-1173,LSM-1134,LSM-1147,LSM-1128,LSM-1014,LSM-5982,LSM-5245,LSM-1023,LSM-36386,LSM-5674,LSM-1051,LSM-1115,LSM-1183,LSM-1135,LSM-1057,LSM-1018,LSM-1099,LSM-1152,LSM-1061,LSM-4255,LSM-1024,LSM-1071,LSM-1101,LSM-1026,LSM-1048,LSM-1160,LSM-1116,LSM-1112,LSM-1072,LSM-1125,LSM-1073,LSM-1126,LSM-1049,LSM-5803,LSM-6019,LSM-1001,LSM-1139,LSM-1149,LSM-1032,LSM-1056,LSM-1052,LSM-1008,LSM-1119,LSM-1142,LSM-1172,LSM-1079,LSM-1080,LSM-1021,LSM-1143,LSM-1111,LSM-1068,LSM-1064,LSM-5970,LSM-1086,LSM-1150,LSM-1109,LSM-1053",Breast cancer,LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1.,Fluorescence imaging apoptosis assay
LDS-1230,20241,HMS LINCS,Imaging,Immunofluorescence,8/25/15,9/3/15,Breast,"MCF7,SK-BR-3,MDA-MB-231,BT-20,Hs578T,MCF10A","LSM-5742,LSM-1035,LSM-1011,LSM-1004,LSM-1159,LSM-1059,LSM-1006,LSM-1007,LSM-1165,LSM-1067,LSM-1041,LSM-1028,LSM-1132,LSM-4257,LSM-1122,LSM-1046,LSM-1191,LSM-1031,LSM-4256,LSM-1162,LSM-1045,LSM-1063,LSM-5577,LSM-6015,LSM-5431,LSM-5545,LSM-6299,LSM-1178,LSM-1148,LSM-1055,LSM-1120,LSM-1117,LSM-1025,LSM-1181,LSM-1010,LSM-1009,LSM-1027,LSM-1141,LSM-1020,LSM-1127,LSM-1069,LSM-1097,LSM-1158,LSM-1040,LSM-1047,LSM-1098,LSM-1108,LSM-1173,LSM-1134,LSM-1147,LSM-1128,LSM-1014,LSM-5982,LSM-5245,LSM-1023,LSM-36386,LSM-5674,LSM-1051,LSM-1115,LSM-1183,LSM-1135,LSM-1057,LSM-1018,LSM-1099,LSM-1152,LSM-1061,LSM-4255,LSM-1024,LSM-1071,LSM-1101,LSM-1026,LSM-1048,LSM-1160,LSM-1116,LSM-1112,LSM-1072,LSM-1125,LSM-1073,LSM-1126,LSM-1049,LSM-5803,LSM-6019,LSM-1001,LSM-1139,LSM-1149,LSM-1032,LSM-1056,LSM-1052,LSM-1008,LSM-1119,LSM-1142,LSM-1172,LSM-1079,LSM-1080,LSM-1021,LSM-1143,LSM-1111,LSM-1068,LSM-1064,LSM-5970,LSM-1086,LSM-1150,LSM-1109,LSM-1053",Breast cancer,LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2.,Fluorescence imaging apoptosis assay
LDS-1231,20242,HMS LINCS,Imaging,Immunofluorescence,8/25/15,9/3/15,Breast,"MCF7,SK-BR-3,MDA-MB-231,BT-20,Hs578T,MCF10A","LSM-5742,LSM-1035,LSM-1011,LSM-1004,LSM-1159,LSM-1059,LSM-1006,LSM-1007,LSM-1165,LSM-1067,LSM-1041,LSM-1028,LSM-1132,LSM-4257,LSM-1122,LSM-1046,LSM-1191,LSM-1031,LSM-4256,LSM-1162,LSM-1045,LSM-1063,LSM-5577,LSM-6015,LSM-5431,LSM-5545,LSM-6299,LSM-1178,LSM-1148,LSM-1055,LSM-1120,LSM-1117,LSM-1025,LSM-1181,LSM-1010,LSM-1009,LSM-1027,LSM-1141,LSM-1020,LSM-1127,LSM-1069,LSM-1097,LSM-1158,LSM-1040,LSM-1047,LSM-1098,LSM-1108,LSM-1173,LSM-1134,LSM-1147,LSM-1128,LSM-1014,LSM-5982,LSM-5245,LSM-1023,LSM-36386,LSM-5674,LSM-1051,LSM-1115,LSM-1183,LSM-1135,LSM-1057,LSM-1018,LSM-1099,LSM-1152,LSM-1061,LSM-4255,LSM-1024,LSM-1071,LSM-1101,LSM-1026,LSM-1048,LSM-1160,LSM-1116,LSM-1112,LSM-1072,LSM-1125,LSM-1073,LSM-1126,LSM-1049,LSM-5803,LSM-6019,LSM-1001,LSM-1139,LSM-1149,LSM-1032,LSM-1056,LSM-1052,LSM-1008,LSM-1119,LSM-1142,LSM-1172,LSM-1079,LSM-1080,LSM-1021,LSM-1143,LSM-1111,LSM-1068,LSM-1064,LSM-5970,LSM-1086,LSM-1150,LSM-1109,LSM-1053",Breast cancer,LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3.,Fluorescence imaging apoptosis assay
LDS-1232,20243,HMS LINCS,Imaging,Immunofluorescence,8/25/15,9/3/15,Breast,"MCF7,SK-BR-3,MDA-MB-231,BT-20,Hs578T,MCF10A","LSM-5742,LSM-1035,LSM-1011,LSM-1004,LSM-1159,LSM-1059,LSM-1006,LSM-1007,LSM-1165,LSM-1067,LSM-1041,LSM-1028,LSM-1132,LSM-4257,LSM-1122,LSM-1046,LSM-1191,LSM-1031,LSM-4256,LSM-1162,LSM-1045,LSM-1063,LSM-5577,LSM-6015,LSM-5431,LSM-5545,LSM-6299,LSM-1178,LSM-1148,LSM-1055,LSM-1120,LSM-1117,LSM-1025,LSM-1181,LSM-1010,LSM-1009,LSM-1027,LSM-1141,LSM-1020,LSM-1127,LSM-1069,LSM-1097,LSM-1158,LSM-1040,LSM-1047,LSM-1098,LSM-1108,LSM-1173,LSM-1134,LSM-1147,LSM-1128,LSM-1014,LSM-5982,LSM-5245,LSM-1023,LSM-36386,LSM-5674,LSM-1051,LSM-1115,LSM-1183,LSM-1135,LSM-1057,LSM-1018,LSM-1099,LSM-1152,LSM-1061,LSM-4255,LSM-1024,LSM-1071,LSM-1101,LSM-1026,LSM-1048,LSM-1160,LSM-1116,LSM-1112,LSM-1072,LSM-1125,LSM-1073,LSM-1126,LSM-1049,LSM-5803,LSM-6019,LSM-1001,LSM-1139,LSM-1149,LSM-1032,LSM-1056,LSM-1052,LSM-1008,LSM-1119,LSM-1142,LSM-1172,LSM-1079,LSM-1080,LSM-1021,LSM-1143,LSM-1111,LSM-1068,LSM-1064,LSM-5970,LSM-1086,LSM-1150,LSM-1109,LSM-1053",Breast cancer,LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 7 of 7: Mean cell count and growth rate across all replicates.,Fluorescence imaging apoptosis assay
LDS-1233,,BroadT LINCS,Transcriptomics,L1000,,7/17/15,"Skin,Lung,Breast,Kidney,Lung,Liver,Large intestine,Prostate","A-375,A549,BT-20,HA1E,HCC515,Hep G2,HME1,Hs 578T,HT-29,LNCaP,MCF10A,MCF7,MDA-MB-231,PC-3,SK-BR-3","LSM-1200,LSM-1207,LSM-6333,LSM-6332,LSM-1175,LSM-1045,LSM-1204,LSM-1180,LSM-1133,LSM-5463,LSM-1035,LSM-1011,LSM-1002,LSM-1003,LSM-1118,LSM-6320,LSM-1034,LSM-1054,LSM-1225,LSM-1004,LSM-1155,LSM-1050,LSM-36357,LSM-5218,LSM-1140,LSM-1159,LSM-1059,LSM-1006,LSM-1007,LSM-1165,LSM-6308,LSM-42751,LSM-1067,LSM-5351,LSM-1041,LSM-1041,LSM-4571,LSM-1164,LSM-1028,LSM-1132,LSM-1144,LSM-1137,LSM-1190,LSM-1178,LSM-6305,LSM-1148,LSM-1189,LSM-1055,LSM-4256,LSM-6264,LSM-1195,LSM-1120,LSM-1186,LSM-5006,LSM-1058,LSM-1610,LSM-1025,LSM-1202,LSM-1187,LSM-1181,LSM-1010,LSM-1009,LSM-1027,LSM-6321,LSM-6342,LSM-1141,LSM-1203,LSM-6303,LSM-1223,LSM-6329,LSM-1020,LSM-6708,LSM-5855,LSM-6306,LSM-1170,LSM-1127,LSM-4811,LSM-1069,LSM-5661,LSM-1097,LSM-4258,LSM-6271,LSM-1158,LSM-1040,LSM-1110,LSM-42745,LSM-6341,LSM-1182,LSM-1047,LSM-4257,LSM-1098,LSM-1373,LSM-1173,LSM-1062,LSM-1134,LSM-1147,LSM-1222,LSM-1030,LSM-1012,LSM-1013,LSM-1128,LSM-42747,LSM-42749,LSM-6328,LSM-1173,LSM-1029,LSM-1014,LSM-6345,LSM-6344,LSM-5982,LSM-5245,LSM-6015,LSM-6343,LSM-1022,LSM-6334,LSM-6335,LSM-1129,LSM-1205,LSM-1023,LSM-6317,LSM-1206,LSM-6339,LSM-6336,LSM-1157,LSM-36386,LSM-1209,LSM-5674,LSM-6318,LSM-1092,LSM-1188,LSM-1031,LSM-1033,LSM-1043,LSM-1065,LSM-1044,LSM-1081,LSM-1198,LSM-1201,LSM-1154,LSM-1196,LSM-1197,LSM-1194,LSM-1074,LSM-1156,LSM-1193,LSM-1051,LSM-1115,LSM-1183,LSM-1135,LSM-36359,LSM-1130,LSM-6323,LSM-6330,LSM-1124,LSM-2481,LSM-1153,LSM-1057,LSM-1066,LSM-5344,LSM-1042,LSM-1018,LSM-1099,LSM-1152,LSM-1070,LSM-2191,LSM-1061,LSM-1122,LSM-42748,LSM-4255,LSM-1184,LSM-6710,LSM-1208,LSM-1024,LSM-1145,LSM-1145,LSM-36398,LSM-1063,LSM-1179,LSM-6340,LSM-1071,LSM-1114,LSM-1101,LSM-1026,LSM-1048,LSM-1160,LSM-1166,LSM-4254,LSM-1116,LSM-1112,LSM-1072,LSM-6331,LSM-1125,LSM-6304,LSM-1073,LSM-1126,LSM-1191,LSM-1049,LSM-1151,LSM-6322,LSM-1163,LSM-5803,LSM-5394,LSM-6019,LSM-1037,LSM-6437,LSM-1226,LSM-2557,LSM-6283,LSM-6324,LSM-1113,LSM-1001,LSM-4947,LSM-1139,LSM-1149,LSM-1174,LSM-1032,LSM-1032,LSM-1168,LSM-1161,LSM-1036,LSM-1121,LSM-42746,LSM-1056,LSM-1171,LSM-6307,LSM-1123,LSM-1052,LSM-1052,LSM-1008,LSM-1119,LSM-1192,LSM-1176,LSM-1167,LSM-1060,LSM-4259,LSM-1142,LSM-1172,LSM-1131,LSM-1005,LSM-1079,LSM-1080,LSM-1021,LSM-1136,LSM-1143,LSM-5578,LSM-1111,LSM-1224,LSM-6325,LSM-6338,LSM-6337,LSM-1199,LSM-36358,LSM-1146,LSM-1068,LSM-3828,LSM-3828,LSM-1169,LSM-5431,LSM-6685,LSM-1064,LSM-5970,LSM-5545,LSM-1085,LSM-5749,LSM-1086,LSM-6297,LSM-1093,LSM-1094,LSM-5577,LSM-6299,LSM-1177,LSM-1150,LSM-1109,LSM-1096,LSM-1053,LSM-5601,LSM-1146","Malignant melanoma,Immmortalized normal,NSCLC,Hepatocellular carcinoma,Ductal carcinoma,Colorectal adenocarcinoma,Fibrocystic,Adenocarcinoma",L1000 Connectivity Map perturbational profiles from Broad Institute LINCS Center for Transcriptomics (NIH U54HL127366),L1000 mRNA profiling assay
LDS-1234,,LINCS PCCSE,Epigenomics,P100,,,"Breast,Prostate,Lung","MCF7,PC-3,A549","LSM-1063,LSM-1103,LSM-1108,LSM-2557,LSM-2597,LSM-3524,LSM-3828,LSM-4571,LSM-4811,LSM-4886,LSM-4923,LSM-4942,LSM-5123,LSM-5351,LSM-5855,LSM-6328,LSM-6330,LSM-6332,LSM-6334,LSM-6335,LSM-6338,LSM-19036,LSM-36361,LSM-36362,LSM-36363,LSM-36364,LSM-36365,LSM-36366,LSM-36368,LSM-36369,LSM-36370,LSM-42750","Adenocarcinoma,Prostate adenocarcinoma,Non-small cell lung carcinoma",P100 Epigenetics compounds,P100 phosphoProtein_Metadata.txt quantification assay
LDS-1235,,LINCS PCCSE,Epigenomics,GCP,,,"Breast,Skin,Prostate,Lung","MCF7,A-375,PC-3,A549","LSM-1063,LSM-1103,LSM-1108,LSM-2557,LSM-2597,LSM-3524,LSM-3828,LSM-4571,LSM-4811,LSM-4886,LSM-4923,LSM-4942,LSM-5123,LSM-5351,LSM-5855,LSM-6328,LSM-6330,LSM-6332,LSM-6334,LSM-6335,LSM-6338,LSM-19036,LSM-36361,LSM-36362,LSM-36363,LSM-36364,LSM-36365,LSM-36366,LSM-36368,LSM-36369,LSM-36370,LSM-42750","Adenocarcinoma, Melanoma, Prostate adenocarcinoma, Non-small cell lung carcinoma",,Global chromatin epigenetic profiling assay
LDS-1236,,LINCS PCCSE,Epigenomics,GCP,,,,NPC,"LSM-1074,LSM-1103,LSM-1139,LSM-1141,LSM-1145,LSM-1181,LSM-1217,LSM-1471,LSM-2135,LSM-2787,LSM-3557,LSM-3828,LSM-4192,LSM-4521,LSM-5512,LSM-6264,LSM-6348,LSM-36361,LSM-36971,LSM-37157,LSM-42752,LSM-42753,LSM-42754,LSM-42755,LSM-42756,LSM-42757,LSM-42758,LSM-42759,LSM-42760,LSM-42761,LSM-42773",,,Global chromatin epigenetic profiling assay
LDS-1237,,DToxS,Transcriptomics,RNA-Seq,6/30/15,,Heart,HCM,"LSM-6555,LSM-3365,LSM-2850,LSM-1176,LSM-36378,LSM-2843,LSM-1008,LSM-5258,LSM-5038,LSM-1023,LSM-2160,LSM-5933,LSM-1297,LSM-3493",,,
LDS-1238,,NeuroLINCS,Transcriptomics,RNA-Seq,,,,iPSC,,,,RNA-seq gene expression profiling assay
LDS-1239,,DToxS,Transcriptomics,RNA-Seq,8/20/15,,Heart,HCM,"LSM-6555,LSM-2850,LSM-3365,LSM-1176,LSM-24954,LSM-1008,LSM-5258,LSM-5038,LSM-2280,LSM-1023,LSM-1097,LSM-5725,LSM-1020,LSM-5470,LSM-5690,LSM-1227,LSM-1190,LSM-1199,LSM-1051,LSM-1114,LSM-1139,LSM-5742,LSM-3493,LSM-5933,LSM-1297",,The overall goal is to develop robust cellular signatures for drug-induced toxicity and toxicity mitigation. These signatures will be established by exposing cells to drugs and drug combinations in culture followed by RNA sequencing.,
LDS-1240,,MEP LINCS,Imaging,MEMA ,,,Prostate,PC3,,Prostate cancer,MEP-LINCs PC3 SS2,MEMA cell growth assay
LDS-1242,,HMS LINCS,Imaging,Immunofluorescence,,,Skin,COLO858,,Melanoma,,Fluorescence imaging cell cycle state assay
LDS-1249,20244,HMS LINCS,Imaging,Immunofluorescence,12/16/15,11/13/15,Breast,"BT-20,MCF 10A,MCF7,MDA-MB-231,Hs578T,SK-BR-3",,Breast cancer,High-content imaging of six breast cancer cell lines treated with a library of small molecule kinase inhibitors.,Fluorescence imaging cell viability assay
LDS-1250,20245,HMS LINCS,Imaging,Immunofluorescence,12/23/15,11/13/15,Breast,"MCF7,SK-BR-3,MDA-MB-231,BT-20,Hs578T,MCF10A","LSM-1001,LSM-1004,LSM-1006,LSM-1007,LSM-1008,LSM-1009,LSM-1010,LSM-1011,LSM-1014,LSM-5982,LSM-5245,LSM-6015,LSM-1018,LSM-5674,LSM-1020,LSM-1021,LSM-1023,LSM-1024,LSM-1025,LSM-1026,LSM-1027,LSM-1028,LSM-1031,LSM-1032,LSM-1035,LSM-5431,LSM-1040,LSM-1041,LSM-1045,LSM-1046,LSM-1047,LSM-1048,LSM-1049,LSM-1051,LSM-1052,LSM-1053,LSM-1055,LSM-1056,LSM-1057,LSM-1059,LSM-1061,LSM-1063,LSM-1064,LSM-1067,LSM-1068,LSM-1069,LSM-1071,LSM-1072,LSM-1073,LSM-5803,LSM-6019,LSM-1079,LSM-1080,LSM-5545,LSM-5970,LSM-1086,LSM-5577,LSM-6299,LSM-1097,LSM-1098,LSM-1099,LSM-36386,LSM-1101,LSM-1108,LSM-1109,LSM-1111,LSM-1112,LSM-1115,LSM-1116,LSM-1117,LSM-1119,LSM-1120,LSM-1122,LSM-1125,LSM-1126,LSM-1127,LSM-1128,LSM-1132,LSM-1134,LSM-1135,LSM-1139,LSM-1141,LSM-1142,LSM-1143,LSM-1147,LSM-1148,LSM-1149,LSM-1150,LSM-1152,LSM-1158,LSM-1159,LSM-1160,LSM-1162,LSM-1165,LSM-1172,LSM-1173,LSM-1178,LSM-1181,LSM-1183,LSM-1191,LSM-4255,LSM-4256,LSM-4257,LSM-2481,LSM-6548,LSM-668",Breast cancer,LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1.,Fluorescence imaging apoptosis assay
LDS-1251,20246,HMS LINCS,Imaging,Immunofluorescence,12/23/15,11/13/15,Breast,"MCF7,SK-BR-3,MDA-MB-231,BT-20,Hs578T,MCF10A","LSM-1001,LSM-1004,LSM-1006,LSM-1007,LSM-1008,LSM-1009,LSM-1010,LSM-1011,LSM-1014,LSM-5982,LSM-5245,LSM-6015,LSM-1018,LSM-5674,LSM-1020,LSM-1021,LSM-1023,LSM-1024,LSM-1025,LSM-1026,LSM-1027,LSM-1028,LSM-1031,LSM-1032,LSM-1035,LSM-5431,LSM-1040,LSM-1041,LSM-1045,LSM-1046,LSM-1047,LSM-1048,LSM-1049,LSM-1051,LSM-1052,LSM-1053,LSM-1055,LSM-1056,LSM-1057,LSM-1059,LSM-1061,LSM-1063,LSM-1064,LSM-1067,LSM-1068,LSM-1069,LSM-1071,LSM-1072,LSM-1073,LSM-5803,LSM-6019,LSM-1079,LSM-1080,LSM-5545,LSM-5970,LSM-1086,LSM-5577,LSM-6299,LSM-1097,LSM-1098,LSM-1099,LSM-36386,LSM-1101,LSM-1108,LSM-1109,LSM-1111,LSM-1112,LSM-1115,LSM-1116,LSM-1117,LSM-1119,LSM-1120,LSM-1122,LSM-1125,LSM-1126,LSM-1127,LSM-1128,LSM-1132,LSM-1134,LSM-1135,LSM-1139,LSM-1141,LSM-1142,LSM-1143,LSM-1147,LSM-1148,LSM-1149,LSM-1150,LSM-1152,LSM-1158,LSM-1159,LSM-1160,LSM-1162,LSM-1165,LSM-1172,LSM-1173,LSM-1178,LSM-1181,LSM-1183,LSM-1191,LSM-4255,LSM-4256,LSM-4257,LSM-2481,LSM-6548,LSM-668",Breast cancer,LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2.,Fluorescence imaging apoptosis assay
LDS-1252,20247,HMS LINCS,Imaging,Immunofluorescence,12/23/15,11/13/15,Breast,"MCF7,SK-BR-3,MDA-MB-231,BT-20,Hs578T,MCF10A","LSM-1001,LSM-1004,LSM-1006,LSM-1007,LSM-1008,LSM-1009,LSM-1010,LSM-1011,LSM-1014,LSM-5982,LSM-5245,LSM-6015,LSM-1018,LSM-5674,LSM-1020,LSM-1021,LSM-1023,LSM-1024,LSM-1025,LSM-1026,LSM-1027,LSM-1028,LSM-1031,LSM-1032,LSM-1035,LSM-5431,LSM-1040,LSM-1041,LSM-1045,LSM-1046,LSM-1047,LSM-1048,LSM-1049,LSM-1051,LSM-1052,LSM-1053,LSM-1055,LSM-1056,LSM-1057,LSM-1059,LSM-1061,LSM-1063,LSM-1064,LSM-1067,LSM-1068,LSM-1069,LSM-1071,LSM-1072,LSM-1073,LSM-5803,LSM-6019,LSM-1079,LSM-1080,LSM-5545,LSM-5970,LSM-1086,LSM-5577,LSM-6299,LSM-1097,LSM-1098,LSM-1099,LSM-36386,LSM-1101,LSM-1108,LSM-1109,LSM-1111,LSM-1112,LSM-1115,LSM-1116,LSM-1117,LSM-1119,LSM-1120,LSM-1122,LSM-1125,LSM-1126,LSM-1127,LSM-1128,LSM-1132,LSM-1134,LSM-1135,LSM-1139,LSM-1141,LSM-1142,LSM-1143,LSM-1147,LSM-1148,LSM-1149,LSM-1150,LSM-1152,LSM-1158,LSM-1159,LSM-1160,LSM-1162,LSM-1165,LSM-1172,LSM-1173,LSM-1178,LSM-1181,LSM-1183,LSM-1191,LSM-4255,LSM-4256,LSM-4257,LSM-2481,LSM-6548,LSM-668",Breast cancer,LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3.,Fluorescence imaging apoptosis assay
LDS-1253,20248,HMS LINCS,Imaging,Immunofluorescence,12/23/15,11/13/15,Breast,"MCF7,SK-BR-3,MDA-MB-231,BT-20,Hs578T,MCF10A","LSM-1001,LSM-1004,LSM-1006,LSM-1007,LSM-1008,LSM-1009,LSM-1010,LSM-1011,LSM-1014,LSM-5982,LSM-5245,LSM-6015,LSM-1018,LSM-5674,LSM-1020,LSM-1021,LSM-1023,LSM-1024,LSM-1025,LSM-1026,LSM-1027,LSM-1028,LSM-1031,LSM-1032,LSM-1035,LSM-5431,LSM-1040,LSM-1041,LSM-1045,LSM-1046,LSM-1047,LSM-1048,LSM-1049,LSM-1051,LSM-1052,LSM-1053,LSM-1055,LSM-1056,LSM-1057,LSM-1059,LSM-1061,LSM-1063,LSM-1064,LSM-1067,LSM-1068,LSM-1069,LSM-1071,LSM-1072,LSM-1073,LSM-5803,LSM-6019,LSM-1079,LSM-1080,LSM-5545,LSM-5970,LSM-1086,LSM-5577,LSM-6299,LSM-1097,LSM-1098,LSM-1099,LSM-36386,LSM-1101,LSM-1108,LSM-1109,LSM-1111,LSM-1112,LSM-1115,LSM-1116,LSM-1117,LSM-1119,LSM-1120,LSM-1122,LSM-1125,LSM-1126,LSM-1127,LSM-1128,LSM-1132,LSM-1134,LSM-1135,LSM-1139,LSM-1141,LSM-1142,LSM-1143,LSM-1147,LSM-1148,LSM-1149,LSM-1150,LSM-1152,LSM-1158,LSM-1159,LSM-1160,LSM-1162,LSM-1165,LSM-1172,LSM-1173,LSM-1178,LSM-1181,LSM-1183,LSM-1191,LSM-4255,LSM-4256,LSM-4257,LSM-2481,LSM-6548,LSM-6685",Breast cancer,LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1.,Fluorescence imaging apoptosis assay
LDS-1254,20249,HMS LINCS,Imaging,Immunofluorescence,12/23/15,11/13/15,Breast,"MCF7,SK-BR-3,MDA-MB-231,BT-20,Hs578T,MCF10A","LSM-1001,LSM-1004,LSM-1006,LSM-1007,LSM-1008,LSM-1009,LSM-1010,LSM-1011,LSM-1014,LSM-5982,LSM-5245,LSM-6015,LSM-1018,LSM-5674,LSM-1020,LSM-1021,LSM-1023,LSM-1024,LSM-1025,LSM-1026,LSM-1027,LSM-1028,LSM-1031,LSM-1032,LSM-1035,LSM-5431,LSM-1040,LSM-1041,LSM-1045,LSM-1046,LSM-1047,LSM-1048,LSM-1049,LSM-1051,LSM-1052,LSM-1053,LSM-1055,LSM-1056,LSM-1057,LSM-1059,LSM-1061,LSM-1063,LSM-1064,LSM-1067,LSM-1068,LSM-1069,LSM-1071,LSM-1072,LSM-1073,LSM-5803,LSM-6019,LSM-1079,LSM-1080,LSM-5545,LSM-5970,LSM-1086,LSM-5577,LSM-6299,LSM-1097,LSM-1098,LSM-1099,LSM-36386,LSM-1101,LSM-1108,LSM-1109,LSM-1111,LSM-1112,LSM-1115,LSM-1116,LSM-1117,LSM-1119,LSM-1120,LSM-1122,LSM-1125,LSM-1126,LSM-1127,LSM-1128,LSM-1132,LSM-1134,LSM-1135,LSM-1139,LSM-1141,LSM-1142,LSM-1143,LSM-1147,LSM-1148,LSM-1149,LSM-1150,LSM-1152,LSM-1158,LSM-1159,LSM-1160,LSM-1162,LSM-1165,LSM-1172,LSM-1173,LSM-1178,LSM-1181,LSM-1183,LSM-1191,LSM-4255,LSM-4256,LSM-4257,LSM-2481,LSM-6548,LSM-6685",Breast cancer,LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2.,Fluorescence imaging apoptosis assay
LDS-1255,20250,HMS LINCS,Imaging,Immunofluorescence,12/23/15,11/13/15,Breast,"MCF7,SK-BR-3,MDA-MB-231,BT-20,Hs578T,MCF10A","LSM-1001,LSM-1004,LSM-1006,LSM-1007,LSM-1008,LSM-1009,LSM-1010,LSM-1011,LSM-1014,LSM-5982,LSM-5245,LSM-6015,LSM-1018,LSM-5674,LSM-1020,LSM-1021,LSM-1023,LSM-1024,LSM-1025,LSM-1026,LSM-1027,LSM-1028,LSM-1031,LSM-1032,LSM-1035,LSM-5431,LSM-1040,LSM-1041,LSM-1045,LSM-1046,LSM-1047,LSM-1048,LSM-1049,LSM-1051,LSM-1052,LSM-1053,LSM-1055,LSM-1056,LSM-1057,LSM-1059,LSM-1061,LSM-1063,LSM-1064,LSM-1067,LSM-1068,LSM-1069,LSM-1071,LSM-1072,LSM-1073,LSM-5803,LSM-6019,LSM-1079,LSM-1080,LSM-5545,LSM-5970,LSM-1086,LSM-5577,LSM-6299,LSM-1097,LSM-1098,LSM-1099,LSM-36386,LSM-1101,LSM-1108,LSM-1109,LSM-1111,LSM-1112,LSM-1115,LSM-1116,LSM-1117,LSM-1119,LSM-1120,LSM-1122,LSM-1125,LSM-1126,LSM-1127,LSM-1128,LSM-1132,LSM-1134,LSM-1135,LSM-1139,LSM-1141,LSM-1142,LSM-1143,LSM-1147,LSM-1148,LSM-1149,LSM-1150,LSM-1152,LSM-1158,LSM-1159,LSM-1160,LSM-1162,LSM-1165,LSM-1172,LSM-1173,LSM-1178,LSM-1181,LSM-1183,LSM-1191,LSM-4255,LSM-4256,LSM-4257,LSM-2481,LSM-6548,LSM-668",Breast cancer,LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3.,Fluorescence imaging apoptosis assay
LDS-1256,20251,HMS LINCS,Imaging,Immunofluorescence,12/23/15,11/13/15,Breast,"MCF7,SK-BR-3,MDA-MB-231,BT-20,Hs578T,MCF10A","LSM-1001,LSM-1004,LSM-1006,LSM-1007,LSM-1008,LSM-1009,LSM-1010,LSM-1011,LSM-1014,LSM-5982,LSM-5245,LSM-6015,LSM-1018,LSM-5674,LSM-1020,LSM-1021,LSM-1023,LSM-1024,LSM-1025,LSM-1026,LSM-1027,LSM-1028,LSM-1031,LSM-1032,LSM-1035,LSM-5431,LSM-1040,LSM-1041,LSM-1045,LSM-1046,LSM-1047,LSM-1048,LSM-1049,LSM-1051,LSM-1052,LSM-1053,LSM-1055,LSM-1056,LSM-1057,LSM-1059,LSM-1061,LSM-1063,LSM-1064,LSM-1067,LSM-1068,LSM-1069,LSM-1071,LSM-1072,LSM-1073,LSM-5803,LSM-6019,LSM-1079,LSM-1080,LSM-5545,LSM-5970,LSM-1086,LSM-5577,LSM-6299,LSM-1097,LSM-1098,LSM-1099,LSM-36386,LSM-1101,LSM-1108,LSM-1109,LSM-1111,LSM-1112,LSM-1115,LSM-1116,LSM-1117,LSM-1119,LSM-1120,LSM-1122,LSM-1125,LSM-1126,LSM-1127,LSM-1128,LSM-1132,LSM-1134,LSM-1135,LSM-1139,LSM-1141,LSM-1142,LSM-1143,LSM-1147,LSM-1148,LSM-1149,LSM-1150,LSM-1152,LSM-1158,LSM-1159,LSM-1160,LSM-1162,LSM-1165,LSM-1172,LSM-1173,LSM-1178,LSM-1181,LSM-1183,LSM-1191,LSM-4255,LSM-4256,LSM-4257,LSM-2481,LSM-6548,LSM-6685",Breast cancer,LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 14 of 15: Mean cell count and mean normalized growth rate inhibition values across all replicates.,Fluorescence imaging apoptosis assay
LDS-1257,20252,HMS LINCS,Imaging,Analysis,1/7/16,11/13/15,Breast,"MCF7,SK-BR-3,MDA-MB-231,BT-20,Hs578T,MCF10A","LSM-1001,LSM-1004,LSM-1006,LSM-1007,LSM-1008,LSM-1009,LSM-1010,LSM-1011,LSM-1014,LSM-5982,LSM-5245,LSM-6015,LSM-1018,LSM-5674,LSM-1020,LSM-1021,LSM-1023,LSM-1024,LSM-1025,LSM-1026,LSM-1027,LSM-1028,LSM-1031,LSM-1032,LSM-1035,LSM-5431,LSM-1040,LSM-1041,LSM-1045,LSM-1046,LSM-1047,LSM-1048,LSM-1049,LSM-1051,LSM-1052,LSM-1053,LSM-1055,LSM-1056,LSM-1057,LSM-1059,LSM-1061,LSM-1063,LSM-1064,LSM-1067,LSM-1068,LSM-1069,LSM-1071,LSM-1072,LSM-1073,LSM-5803,LSM-6019,LSM-1079,LSM-1080,LSM-5545,LSM-5970,LSM-1086,LSM-5577,LSM-6299,LSM-1097,LSM-1098,LSM-1099,LSM-36386,LSM-1101,LSM-1108,LSM-1109,LSM-1111,LSM-1112,LSM-1115,LSM-1116,LSM-1117,LSM-1119,LSM-1120,LSM-1122,LSM-1125,LSM-1126,LSM-1127,LSM-1128,LSM-1132,LSM-1134,LSM-1135,LSM-1139,LSM-1141,LSM-1142,LSM-1143,LSM-1147,LSM-1148,LSM-1149,LSM-1150,LSM-1152,LSM-1158,LSM-1159,LSM-1160,LSM-1162,LSM-1165,LSM-1172,LSM-1173,LSM-1178,LSM-1181,LSM-1183,LSM-1191,LSM-4255,LSM-4256,LSM-4257,LSM-2481,LSM-6548,LSM-6685",Breast cancer,LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 15 of 15: Calculated dose response metrics.,Fluorescence imaging apoptosis assay
LDS-1261,20256,HMS LINCS,Imaging,Immunofluorescence,2/4/16,11/13/15,Breast,"MCF7,MCF10A,MDA-MB-231,BT-20,SK-BR-3","LSM-1147,LSM-1099,LSM-1049,LSM-1024,LSM-1071,LSM-1097,LSM-1051,LSM-1135",Breast cancer,Breast Cancer Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 1 of 3: Cell count and normalized growth rate inhibition values.,Fluorescence imaging cell viability assay
LDS-1262,20257,HMS LINCS,Imaging,Immunofluorescence,2/4/16,11/13/15,Breast,"MCF7,MCF10A,MDA-MB-231,BT-20,SK-BR-3","LSM-1147,LSM-1099,LSM-1049,LSM-1024,LSM-1071,LSM-1097,LSM-1051,LSM-1135",Breast cancer,Breast Cancer Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 2 of 3: Mean cell count and mean normalized growth rate inhibition values across all replicates.,Fluorescence imaging cell viability assay
LDS-1263,20258,HMS LINCS,Imaging,Analysis,2/4/16,11/13/15,Breast,"MCF7,MCF10A,MDA-MB-231,BT-20,SK-BR-3","LSM-1147,LSM-1099,LSM-1049,LSM-1024,LSM-1071,LSM-1097,LSM-1051,LSM-1135",Breast cancer,Breast Cancer Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 3 of 3: Calculated dose response metrics.,Fluorescence imaging cell viability assay
